Industry Partnerships & Commercialization
The Industry Partnerships and Commercialization (IP&C) Office at The Hospital for Sick Children (SickKids) champions the identification, development, and commercialization of cutting-edge health innovations from SickKids researchers, partnering with industry and investors to translate these innovations into impactful healthcare services and products worldwide.
Transforming SickKids Innovation into Global Health Impact
At IP&C, our team comprises individuals with deep scientific expertise and extensive experience in patenting, licensing, commercial transactions, and startup ventures.
We go beyond traditional tech transfer roles by assisting SickKids Innovators in de-risking their discoveries, maximizing their value, and aligning with investor interests.
Discover how we connect ideas, industry, and investors to create efficient pathways for commercializing research and technology developed at SickKids by watching our video!
Tap Into the Innovation Ecosystem at the SickKids Research Institute
IP&C operates out of the Peter Gilgan Centre for Research and Learning and is a division of the SickKids Research Institute – the largest hospital-based pediatric health institute in Canada.
Canada's most research-intensive hospital
Top 10 Canadian institutions for licensing revenue generated
*AUTM Licensing survey for FY 2022
Over 600 active patents, 232 US Patents issued
World's 2nd Best Pediatric Hospital
*Newsweek World’s Best Specialized Hospitals 2023
Latest News
A novel cell-penetrant delivery platform applied to a pan-Ras targeting anti-cancer therapy Roman Melnyk, PhD Senior Scientist | Molecular Medicine Technology 1-Pager Lab Website [...]
Novel therapeutic compositions for degrading bacterial and fungal biofilms P. Lynne Howell, PhD Senior Scientist | Molecular Medicine Technology 1-Pager Lab Website [...]
SickKids Ranked One of Canada's Top 40 Research Hospitals for 2021 SickKids has once again been named one of Canada’s top research hospitals by Research Infosource. [...]
Pfizer Completes Acquisition of Trillium Therapeutics On November 17, 2021, Pfizer Inc. announced the successful completion of its acquisition of Trillium Therapeutics, a clinical stage immuno-oncology [...]
